Bioavailability Enhancement of Astilbin in Rats through Zein-Caseinate Nanoparticles.
Astilbin-encapsulated zein-caseinate nanoparticles were fabricated through the antisolvent method. The encapsulation and loading efficiency of astilbin in the nanoparticles were determined by high-performance liquid chromatography. The nanoparticles were characterized by particle size, ζ potential, redispersibility, scanning electron microscopy, X-ray diffraction (XRD), Fourier transform infrared spectroscopy, and differential scanning calorimetry (DSC). Under the optimal formulation of astilbin, zein, and sodium caseinate with a mass ratio of 1:1:2, the size and ζ potential of the nanoparticles were 152.9 nm and -40.43 mV, respectively, while the encapsulation and loading efficiency of astilbin were 80.1 and 21.8%, respectively. The nanoparticles had good redispersibility in water without a particle size change after freeze drying. The nanoparticles showed a spherical shape with a smooth surface. XRD and DSC analyses showed that astilbin existed in amorphous form in the nanoparticles. The interactions between astilbin and the protein were found, and astilbin was encapsulated in nanoparticles rather than adsorbed. The diffusion of astilbin from nanoparticles was significantly faster than that of astilbin suspensions in both simulated gastric and intestinal fluids. Astilbin was relatively stable in simulated intestinal fluids, and the encapsulation in the nanoparticles showed a slight stability improvement effect. A pharmacokinetic study showed that the absolute bioavailability of astilbin was improved from 0.32 to 4.40% in rats through nanoparticle fabrication.